Predictive value of inflammatory-related factors on the efficacy of adjuvant dexamethasone in the treatment of children with refractory suppurative meningitis
Abstract
Purpose: The aim of this study was to figure out the predictive value of inflammatory-linked factors on the efficacy of dexamethasone adjuvant therapy for refractory suppurative meningitis in children.
Methods: Using regression analysis method, 38 children with refractory purulent meningitis, 40 children with purulent meningitis, and 40 healthy children who came to Qingtian County People's Hospital of Lishui City for physical examination during the same period were selected as the research objects, and assigned into the experimental, the control and the healthy groups. The inflammation-linked factors in the three groups were compared, and multivariate Logisitic regression was applied to analyze the predictive indicators and predictive efficacy of dexamethasone treatment in children with refractory suppurative meningitis.
Results: CRP, TNF-α, IL-6, PCT and IL-1β were higher in the study group vs. the control and the healthy, and in the control vs. the healthy (P < 0.05). Multivariate Logisitic regression analysis clarified the predictors of the efficacy of dexamethasone treatment in children with refractory suppurative meningitis were CRP, TNF-α, IL-6, PCT, and IL-1β, which all had good predictive performance, and among which CRP and IL-1β had better predictive performance.
Conclusion: Inflammatory-linked factors have a certain predictive value for the efficacy of dexamethasone adjuvant therapy for refractory suppurative meningitis in children.
References
[2]Müller A, Schramm DB, Kleynhans J,et al. Cytokine response in cerebrospinal fluid of meningitispatients and outcome associated with pneumococcal serotype[J]. Sci Rep. 2021,11(1):19920.
[3]Tsai HC, Chen YH. Dexamethasone downregulates the expressions of MMP-9 andoxidative stress in mice with eosinophilic meningitis caused byAngiostrongylus cantonensis infection. Parasitology. 2021,148(2):187-197.
[4] Zaifang Jiang, Kunling Shen, Ying Shen. Zhu Futang Practical Pediatrics [M] the 8th edition. Beijing: People's Health Publishing House, 2014: 981-990.
[5]Luo Y, Liao Z, Shu J,et al. Observation and analysis of the efficacyof dexamethasone in combination with anti-infectious treatment on the pediatricrefractory purulent meningitis[J]. Pak J Pharm Sci. 2020,33(1(Special)):489-494.
[6]Dujari S, Gummidipundi S, He Z,et al. Administration of Dexamethasone forBacterial Meningitis: An Unreliable Quality Measure[J]. Neurohospitalist. 2021,11(2):101-106.
[7]Dias SP, Brouwer MC, van de Beek D. Sex-based differences in the response todexamethasone in bacterial meningitis: Analysis of the European dexamethasone inadulthood bacterial meningitis study[J]. Br J Clin Pharmacol. 2020,86(2):386-391.
[8]Kitonsa J, Nsubuga R, Mayanja Y,et al. Determinants of two-year mortalityamong HIV positive patients with Cryptococcal meningitis initiating standardantifungal treatment with or without adjunctive dexamethasone in Uganda[J]. PLoSNegl Trop Dis. 2020,14(11):e0008823.
[9]Whitworth LJ, Troll R, Pagán AJ,et al. Elevatedcerebrospinal fluid cytokine levels in tuberculous meningitis predict survivalin response to dexamethasone[J]. Proc Natl Acad Sci U S A. 2021,118(10):e2024852118.
[10]Shiomi Y, Fujiwara S, Morihisa Y,et al.[Bacterial Meningitis and Suppurative Thrombophlebitis after Trigger PointInjections: A Case Report][J]. Brain Nerve. 2021,73(6):737-740.
[11]Huang X, Chen X, Tong SW,et al. Kikuchi-Fujimotodisease complicated by aseptic meningitis and hemophagocytosis successfullytreated with intrathecal dexamethasone[J]. Heliyon. 2020,6(6):e04193.
[12]Beardsley J, Hoang NLT, Kibengo FM,et al. Do Intracerebral CytokineResponses Explain the Harmful Effects of Dexamethasone in Human ImmunodeficiencyVirus-associated Cryptococcal Meningitis[J]? Clin Infect Dis. 2019,68(9):1494-1501.
[13]Freer S, House DT, Hallman MG. Viral Meningitis: A Pediatric Case Study[J]. AdvEmerg Nurs J. 2020,42(4):254-261.
[14]Debray A, Nathanson S, Moulin F,et al. Eosinopenia as a markerof diagnosis and prognostic to distinguish bacterial from aseptic meningitis inpediatrics[J]. Eur J Clin Microbiol Infect Dis. 2019,38(10):1821-1827.
[15]Liu X,Lin S, Du K,et al. Procalcitonin measurement usingantibody-conjugated fluorescent microspheres distinguishes atypical bacterialmeningitis from viral encephalitis in children[J]. Anal Biochem. 2021,1(626):114219.
[16]Karki R, Sharma BR, Tuladhar S,et al. Synergism of TNF-α and IFN-γ Triggers InflammatoryCell Death, Tissue Damage, and Mortality in SARS-CoV-2 Infection and CytokineShock Syndromes[J]. Cell. 2021,84(1):149-168.e17.
[17]Taus F, Salvagno G, Canè S,et al. Platelets PromoteThromboinflammation in SARS-CoV-2 Pneumonia[J]. Arterioscler Thromb Vasc Biol. 2020,40(12):2975-2989.
[18]Ulhaq ZS, Soraya GV. Anti-IL-6 receptor antibody treatment for severeCOVID-19 and the potential implication of IL-6 gene polymorphisms in novelcoronavirus pneumonia[J]. Med Clin (Barc). 2020,155(12):548-556.
[19]Bedetti L, Marrozzini L, Baraldi A,et al. Pitfalls in the diagnosis of meningitis in neonates and younginfants: the role of lumbar puncture[J]. J Matern Fetal Neonatal Med. 2019,32(23):4029-4035.
[20]Keus AMJMH, Peeters DD, Bekker VV,et al. Neonatal Meningitis and Subdural Empyema Caused by an UnusualPathogen[J]. Pediatr Infect Dis J. 2019,38(12):e329-e331.
Copyright (c) 2023 XunLing Yuan, XiaoMei Zhong, QingJun Niu
This work is licensed under a Creative Commons Attribution 4.0 International License.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.